<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180478</url>
  </required_header>
  <id_info>
    <org_study_id>10-004660</org_study_id>
    <nct_id>NCT01180478</nct_id>
  </id_info>
  <brief_title>Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer</brief_title>
  <official_title>A Multi-center, International Study to Compare Use of Narrow Band Imaging (NBI) Versus White Light(WL) During Transurethral Resection of Bladder Tumors (TURB) to Asses Recurrence of Bladder Cancer in Terms of Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Office of the Endourological Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Research Office of the Endourological Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the recurrence rate at 1 year following Narrow Band
      Imaging and trans-urethral resection of bladder tumor with White Light and TURB in patients
      with non-muscle invasive bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently bladder tumors are diagnosed visually with standard cystoscopy that uses white
      light, or light that is generated encompassing the entire visual spectrum. Some tumors such
      as carcinoma in situ may not be visible using white light and require patients to undergo
      random bladder biopsies in order to find the cancer. Recently the development of photodynamic
      agents have been shown to enhance these procedures to accomplish better resection and
      identify over-looked tumors. However, these methods often require the instillation of dyes
      into the bladder as well as specialized cystoscopes. Narrow band imaging (NBI) is now
      available which uses a special filter to limit the light to only certain wavelengths which
      allows the identification of areas of increased vascularity or abnormalities without the need
      for dyes. NBI has been investigated in gastro-intestinal disease and found to be beneficial.
      Early reports in urology suggest that this technology may reduce the number of tumors that
      are missed which could impact the recurrence rate of bladder tumors, but this is not known at
      this time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of Bladder Cancer (TURB) (Arm B) in Patients With Non Muscle Invasive (pTa/T1) Bladder Cancer.</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>The primary outcome measure was recurrence rate at 1 year. A recurrence was defined as the new occurrence of a bladder cancer at the same site as or at a different site from the index cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Persistence/Recurrence of Tumors at First 3 Month Follow up After NBI Versus WL Cystoscopy and Tumor Resection</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative Morbidity (30 Days) of TURB Between NBI and WL Resection Using the Clavien System.</measure>
    <time_frame>30 days</time_frame>
    <description>Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions.
Grade II Requiring pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included.
Grade III Requiring surgical, endoscopic or radiological intervention Grade III-a Intervention not under general anaesthesia Grade III-b Intervention under general anaesthesia
Grade IV Life-threatening complication (including CNS complications: brain haemorrhage, ischaemic stroke, subarachnoid bleeding, but excluding transient ischaemic attacks) requiring IC/ICU management Grade IV-a Single organ dysfunction (including dialysis) Grade IV-b Multi-organ dysfunction
Grade V Death of a patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for the Development of Peri-operative Morbidity After Instrumental Treatment.</measure>
    <time_frame>peri-operative</time_frame>
    <description>We looked at different perioperative complications in order to discover peri-operative morbidity after instrumental treatment. The following variables were analyzed: Bleeding, Fever, UTI, Bladder cramps, DVT, CVA/TIA, Lung embolism, Sepsis, Acute Abdomen, and Other perioperative complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rate Related to Additional Treatment Following TURB.</measure>
    <time_frame>Until 135 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">965</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Narrow Band Imaging</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Narrow Band Imaging (NBI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>White Light Trans Urethral Resection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>White Light Trans Urethral Resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>White Light</intervention_name>
    <description>White Light Cystoscopy</description>
    <arm_group_label>White Light Trans Urethral Resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narrow Band Imaging</intervention_name>
    <description>Narrow Band Imaging</description>
    <arm_group_label>Narrow Band Imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for treatment of primary or recurrent non-muscle invasive bladder
             cancer

          -  Patients greater than 18 years of age

          -  No tumors in the upper tract (kidneys or ureters)

          -  No previous pelvic radiation

        Exclusion Criteria:

          -  Gross hematuria at the time of resection making visualization with NBI not possible

          -  Participation in other clinical studies with investigations drugs concurrently or
             within 30 days.

          -  Pregnancy

          -  Conditions associated with a risk of poor compliance or unwilling to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean de la Rosette, MD</last_name>
    <role>Study Director</role>
    <affiliation>AMC University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <results_first_submitted>August 10, 2017</results_first_submitted>
  <results_first_submitted_qc>March 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2018</results_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder Cancer</keyword>
  <keyword>Urothelial carcinoma</keyword>
  <keyword>Stage pTa or pT1</keyword>
  <keyword>NMIBC Ta/T1</keyword>
  <keyword>Narrow Band Imaging</keyword>
  <keyword>White Light Cystoscopy</keyword>
  <keyword>Transurethral resection</keyword>
  <keyword>Superficial bladder tumor</keyword>
  <keyword>Positive urine cytology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Narrow Band Imaging</title>
          <description>Narrow Band Imaging (NBI)
Narrow Band Imaging: Narrow Band Imaging</description>
        </group>
        <group group_id="P2">
          <title>White Light Trans Urethral Resection</title>
          <description>White Light Trans Urethral Resection
White Light: White Light Cystoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="484"/>
                <participants group_id="P2" count="481"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Narrow Band Imaging</title>
          <description>Narrow Band Imaging (NBI)
Narrow Band Imaging: Narrow Band Imaging</description>
        </group>
        <group group_id="B2">
          <title>White Light Trans Urethral Resection</title>
          <description>White Light Trans Urethral Resection
White Light: White Light Cystoscopy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="484"/>
            <count group_id="B2" value="481"/>
            <count group_id="B3" value="965"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="12.5"/>
                    <measurement group_id="B2" value="66.7" spread="12.3"/>
                    <measurement group_id="B3" value="66.24" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="383"/>
                    <measurement group_id="B3" value="773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Arab Emirates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of Bladder Cancer (TURB) (Arm B) in Patients With Non Muscle Invasive (pTa/T1) Bladder Cancer.</title>
        <description>The primary outcome measure was recurrence rate at 1 year. A recurrence was defined as the new occurrence of a bladder cancer at the same site as or at a different site from the index cancer.</description>
        <time_frame>1 year after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narrow Band Imaging</title>
          </group>
          <group group_id="O2">
            <title>White Light</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of Bladder Cancer (TURB) (Arm B) in Patients With Non Muscle Invasive (pTa/T1) Bladder Cancer.</title>
          <description>The primary outcome measure was recurrence rate at 1 year. A recurrence was defined as the new occurrence of a bladder cancer at the same site as or at a different site from the index cancer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The expected recurrence rate in the WL-assisted TURBT group was 35%.14 To detect a clinically relevant difference in recurrence detection rates ≥10% at a 5% significance level and a power of 80%, the required sample size per treatment was calculated to be 329 patients (658 patients in total).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.585</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Persistence/Recurrence of Tumors at First 3 Month Follow up After NBI Versus WL Cystoscopy and Tumor Resection</title>
        <time_frame>3 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narrow Band Imaging</title>
            <description>Narrow Band Imaging (NBI)
Narrow Band Imaging: Narrow Band Imaging</description>
          </group>
          <group group_id="O2">
            <title>White Light Trans Urethral Resection</title>
            <description>White Light Trans Urethral Resection
White Light: White Light Cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Persistence/Recurrence of Tumors at First 3 Month Follow up After NBI Versus WL Cystoscopy and Tumor Resection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.742</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peri-operative Morbidity (30 Days) of TURB Between NBI and WL Resection Using the Clavien System.</title>
        <description>Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions.
Grade II Requiring pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included.
Grade III Requiring surgical, endoscopic or radiological intervention Grade III-a Intervention not under general anaesthesia Grade III-b Intervention under general anaesthesia
Grade IV Life-threatening complication (including CNS complications: brain haemorrhage, ischaemic stroke, subarachnoid bleeding, but excluding transient ischaemic attacks) requiring IC/ICU management Grade IV-a Single organ dysfunction (including dialysis) Grade IV-b Multi-organ dysfunction
Grade V Death of a patient</description>
        <time_frame>30 days</time_frame>
        <population>The Clavien grading of perioperative complications variable contains missings, therefore the valid percentages are presented in the outcome measure data table. The NBI group had 2 missing values, and the WL group had 3 missing values. Therfore, the overall number deviates from 484 and 481.
Below shown is a categorical variable with 8 categories</population>
        <group_list>
          <group group_id="O1">
            <title>Narrow Band Imaging</title>
            <description>Narrow Band Imaging (NBI)
Narrow Band Imaging: Narrow Band Imaging</description>
          </group>
          <group group_id="O2">
            <title>White Light Trans Urethral Resection</title>
            <description>White Light Trans Urethral Resection
White Light: White Light Cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Peri-operative Morbidity (30 Days) of TURB Between NBI and WL Resection Using the Clavien System.</title>
          <description>Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions.
Grade II Requiring pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included.
Grade III Requiring surgical, endoscopic or radiological intervention Grade III-a Intervention not under general anaesthesia Grade III-b Intervention under general anaesthesia
Grade IV Life-threatening complication (including CNS complications: brain haemorrhage, ischaemic stroke, subarachnoid bleeding, but excluding transient ischaemic attacks) requiring IC/ICU management Grade IV-a Single organ dysfunction (including dialysis) Grade IV-b Multi-organ dysfunction
Grade V Death of a patient</description>
          <population>The Clavien grading of perioperative complications variable contains missings, therefore the valid percentages are presented in the outcome measure data table. The NBI group had 2 missing values, and the WL group had 3 missing values. Therfore, the overall number deviates from 484 and 481.
Below shown is a categorical variable with 8 categories</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415"/>
                    <measurement group_id="O2" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analyses refers to comparison of the different 8 categories (one variable) mentioned of the Clavien grading of perioperative complications between Narrow Band Imaging and White Light Trans Urethral Resection.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>Fisher Exact</method>
            <method_desc>The analysis was performed by using the Fisher exact test, because the criteria for using the Chi square test were not met.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for the Development of Peri-operative Morbidity After Instrumental Treatment.</title>
        <description>We looked at different perioperative complications in order to discover peri-operative morbidity after instrumental treatment. The following variables were analyzed: Bleeding, Fever, UTI, Bladder cramps, DVT, CVA/TIA, Lung embolism, Sepsis, Acute Abdomen, and Other perioperative complications.</description>
        <time_frame>peri-operative</time_frame>
        <population>The variables contain missing values, therefore the numbers in the below table differs from the overall numbers reported</population>
        <group_list>
          <group group_id="O1">
            <title>Narrow Band Imaging</title>
            <description>Narrow Band Imaging (NBI)
Narrow Band Imaging: Narrow Band Imaging</description>
          </group>
          <group group_id="O2">
            <title>White Light Trans Urethral Resection</title>
            <description>White Light Trans Urethral Resection
White Light: White Light Cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Development of Peri-operative Morbidity After Instrumental Treatment.</title>
          <description>We looked at different perioperative complications in order to discover peri-operative morbidity after instrumental treatment. The following variables were analyzed: Bleeding, Fever, UTI, Bladder cramps, DVT, CVA/TIA, Lung embolism, Sepsis, Acute Abdomen, and Other perioperative complications.</description>
          <population>The variables contain missing values, therefore the numbers in the below table differs from the overall numbers reported</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bleeding</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="431"/>
                    <count group_id="O2" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="407"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UTI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder cramps</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="407"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DVT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CVA/TIA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="420"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung embolism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="404"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Abdomen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other perioperative complication</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="406"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the numbers in 'Bleeding' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the numbers in 'Fever' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.666</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'UTI' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.569</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'Bladder cramps' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'DVT' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <other_analysis_desc>Non of the participants/patients had DVT. Therefore, the p-value is not available</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'CVA/TIA' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'Lung embolism' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <other_analysis_desc>Non of the participants/patients had a lung embolism. Therefore, no p-value was available</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'Sepsis' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'Acute Abdomen' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison in the number of 'Other perioperative complication' between NBI and WL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence Rate Related to Additional Treatment Following TURB.</title>
        <time_frame>Until 135 days</time_frame>
        <population>Only 61 of the patients in the total population in the NBI group, and 69 of the patients in the total population of the WL group received a Re-TURBT after initial TURBT (within 135 days). These numbers therefore differ and deviate from the Participant Flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>Narrow Band Imaging</title>
            <description>Narrow Band Imaging (NBI)
Narrow Band Imaging: Narrow Band Imaging</description>
          </group>
          <group group_id="O2">
            <title>White Light Trans Urethral Resection</title>
            <description>White Light Trans Urethral Resection
White Light: White Light Cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Rate Related to Additional Treatment Following TURB.</title>
          <population>Only 61 of the patients in the total population in the NBI group, and 69 of the patients in the total population of the WL group received a Re-TURBT after initial TURBT (within 135 days). These numbers therefore differ and deviate from the Participant Flow module.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.553</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only Serious Adverse Events were monitored</desc>
      <group_list>
        <group group_id="E1">
          <title>Narrow Band Imaging</title>
          <description>Narrow Band Imaging (NBI)
Narrow Band Imaging: Narrow Band Imaging</description>
        </group>
        <group group_id="E2">
          <title>White Light Trans Urethral Resection</title>
          <description>White Light Trans Urethral Resection
White Light: White Light Cystoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>patient died of cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of heart attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of asystolia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>rectorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>herniainguinalis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of pancreas cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>patient died of unknown cause</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>euthanasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>galbladder carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of biliary tract cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>campylobacter colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>acute prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>infection of unknown origin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of septicaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>patient died by car accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>obturator kick</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>urethral injury occurred at time of TUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hip's fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>patient died of another neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>radical cystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>transurethral urethrotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died by renal insuffiency and prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>transurethral resection prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>transurethral urinary resection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of kidney failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>radical cystectomy + bricker</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of chest infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>acute exacerbation of COPD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>patient died of respiratory insuffiency by bilaterial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cardiogenic embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>cerebrovascular attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There is a possibility of observer bias favouring NBI as a limitation of this single-blind study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>J. de la Rosette, chairman CROES</name_or_title>
      <organization>CROES</organization>
      <phone>+31 20 5666030</phone>
      <email>info@croesoffice.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

